Soluble triggering receptor expressed on myeloid cells-1 as a new therapeutic molecule in rheumatoid arthritis

Tae Hwan Kim, Sung Jae Choi, Young Ho Lee, Gwan Gyu Song, Jong Dae Ji

    Research output: Contribution to journalArticlepeer-review

    13 Citations (Scopus)

    Abstract

    Triggering receptor expressed on myeloid cells-1 (TREM-1) is a recently identified cell surface receptor that is expressed mainly on monocytes and neutrophils, and plays an important role as an amplifier of inflammatory response in acute and chronic inflammatory conditions. Recent studies suggested that TREM-1 contributes to the pathogenesis of rheumatoid arthritis (RA) and therefore TREM-1 could be a new therapeutic target in RA. In addition to its membrane-bound form, a soluble form of TREM-1 (sTREM-1) exists that is liberated by the proteolytic cleavage of membrane-bound form. This soluble form works as decoy receptor to prevent the binding of its ligand to membrane-bound TREM-1 and to inhibit the effect of TREM-1 activation. Proteolytic cleavage of TNF receptor (TNFR) has been reported and soluble TNFR are capable of binding and neutralizing TNF, thus working as natural TNF antagonist. Currently, etanercept, a soluble TNF-receptor fusion protein has been widely used to treat RA. In this report, we suggest that sTREM-1 can be used as a new therapeutic molecule in RA.

    Original languageEnglish
    Pages (from-to)270-272
    Number of pages3
    JournalMedical Hypotheses
    Volume78
    Issue number2
    DOIs
    Publication statusPublished - 2012 Feb

    ASJC Scopus subject areas

    • Medicine(all)

    Fingerprint

    Dive into the research topics of 'Soluble triggering receptor expressed on myeloid cells-1 as a new therapeutic molecule in rheumatoid arthritis'. Together they form a unique fingerprint.

    Cite this